OAKVILLE HONG KONG CO., LTD. – Trademark Portfolio
Entity Type: 16
OAKVILLE HONG KONG CO., LTD. holds 7 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 4 filings in this category. The portfolio also extends into Class 10 (Medical Apparatus) across 3 Nice Classification classes. Currently, 5 trademarks are registered. Notable registered marks include ACON, MISSION, and ON CALL. The owner is based in HONG KONG.
32 HOLLYWOOD ROAD
9/F KINWICK CENTRE, SUITE 901B
HONG KONG , HK
Showing of trademarks Trademarks
Trademark Classifications
OAKVILLE HONG KONG CO., LTD.'s trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments
Frequently Asked Questions
How many trademarks does OAKVILLE HONG KONG CO., LTD. have?
OAKVILLE HONG KONG CO., LTD. has 7 U.S. trademarks filed with the USPTO. Of these, 5 registered, 2 cancelled.
What trademark classes does OAKVILLE HONG KONG CO., LTD. file in?
OAKVILLE HONG KONG CO., LTD. files trademarks across 3 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus), Class 9 (Computers & Electronics). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are OAKVILLE HONG KONG CO., LTD.'s most well-known trademarks?
OAKVILLE HONG KONG CO., LTD.'s registered trademark portfolio includes well-known marks such as ACON, MISSION, and ON CALL. These are among 5 currently registered trademarks in the portfolio.
What is OAKVILLE HONG KONG CO., LTD.'s trademark registration success rate?
OAKVILLE HONG KONG CO., LTD. has a 71% trademark registration rate, with 5 out of 7 resolved applications resulting in successful registration. Currently, 0 applications are pending review.